Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity^[1][2].

Reveromycin A inhibits protein synthesis in osteoclasts (OCs) by selectively blocking enzymatic activity of isoleucyl-tRNA synthetase^[2].
Reveromycin A (0.3-30 μM; for 24 h) induces apoptosis in OCs through inhibition of protein synthesis^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Reveromycin A (20 mg/kg; twice daily; i.v.; for 3 days) significantly decreases numbers of OCs without affecting numbers of osteoblasts in normal 4-week-old male Sprague-Dawley rats^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

660.79

C₃₆H₅₂O₁₁

134615-37-5

雷弗霉素A

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. H Takahashi , et al. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. J Antibiot (Tokyo). 1992 Sep;45(9):1414-9.

  [2]. Je-Tae Woo, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4729-34.